These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10958592)

  • 21. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Anand A; Anand A; Anand N
    Cancer; 1996 May; 77(9):1959-60. PubMed ID: 8646700
    [No Abstract]   [Full Text] [Related]  

  • 22. Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.
    Trafalis DT; Alifieris C; Krikelis D; Tzogkas N; Stathopoulos GP; Athanassiou AE; Sitaras NM
    Int J Clin Pharmacol Ther; 2012 Jul; 50(7):490-9. PubMed ID: 22578202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
    Sahmoud T; Postmus PE; van Pottelsberghe C; Mattson K; Tammilehto L; Splinter TA; Planting AS; Sutedja T; van Pawel J; van Zandwijk N; Baas P; Roozendaal KJ; Schrijver M; Kirkpatrick A; Van Glabbeke M; Ardizzoni A; Giaccone G
    Eur J Cancer; 1997 Nov; 33(13):2211-5. PubMed ID: 9470808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy for malignant mesothelioma; CAMEO.
    Jett JR; Eagan RT
    Am J Clin Oncol; 1982 Aug; 5(4):429-31. PubMed ID: 7051806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience.
    Perez AT; Domenech GH; Frankel C; Vogel CL
    Cancer Invest; 2002; 20 Suppl 2():22-9. PubMed ID: 12442346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
    Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
    J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma.
    Yap BS; Benjamin RS; Burgess MA; Bodey GP
    Cancer; 1978 Oct; 42(4):1692-6. PubMed ID: 709531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined doxorubicin and radiation therapy in malignant pleural mesothelioma.
    Sinoff C; Falkson G; Sandison AG; De Mûelenaere G
    Cancer Treat Rep; 1982 Aug; 66(8):1605-7. PubMed ID: 7105050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
    Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
    Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of remission in diffuse pleural mesothelioma induced by anticancer chemotherapy with cisplatin and adriamycin].
    Kinoshita S; Yamashita T; Yagi M; Bando H; Tsubura E; Sano T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1872-6. PubMed ID: 4041164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
    Pinto C; Marino A; Guaraldi M; Melotti B; Piana E; Martoni A; Pannuti F
    Am J Clin Oncol; 2001 Apr; 24(2):143-7. PubMed ID: 11319288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
    Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M
    Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
    Rusch V; Saltz L; Venkatraman E; Ginsberg R; McCormack P; Burt M; Markman M; Kelsen D
    J Clin Oncol; 1994 Jun; 12(6):1156-63. PubMed ID: 8201377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.
    Harvey VJ; Slevin ML; Ponder BA; Blackshaw AJ; Wrigley PF
    Cancer; 1984 Sep; 54(6):961-4. PubMed ID: 6467141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
    van Breukelen FJ; Mattson K; Giaccone G; van Zandwijk N; Planteydt HT; Kirkpatrick A; Dalesio O
    Eur J Cancer; 1991; 27(12):1627-9. PubMed ID: 1782071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of topotecan for the treatment of mesothelioma.
    Maksymiuk AW; Marschke RF; Tazelaar HD; Grill J; Nair S; Marks RS; Brooks BJ; Mailliard JA; Burton GM; Jett JR
    Am J Clin Oncol; 1998 Dec; 21(6):610-3. PubMed ID: 9856666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of vincristine in malignant mesothelioma--a negative report.
    Mårtensson G; Sörenson S
    Cancer Chemother Pharmacol; 1989; 24(2):133-4. PubMed ID: 2731313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of six cases of mesothelioma with doxorubicin and cisplatin.
    Zidar BL; Pugh RP; Schiffer LM; Raju RN; Vaidya KA; Bloom RL; Horne D; Baker LH
    Cancer; 1983 Nov; 52(10):1788-91. PubMed ID: 6684983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
    Krug LM; Heelan RT; Kris MG; Venkatraman E; Sirotnak FM
    J Thorac Oncol; 2007 Apr; 2(4):317-20. PubMed ID: 17409804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.